MaaT Pharma SA (EPA:MAAT)
France · Delayed Price · Currency is EUR 1.010
-0.020 (-1.94%)
Oct 2, 2026, 5:35 PM CET
MaaT Pharma Stock Forecast
EPA-MAAT's stock price has decreased by -75.72% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 2 analysts polled by S&P Global, MaaT Pharma stock has a consensus rating of "Buy" and an average price target of €6.50. The average 1-year stock price forecast is 543.56% higher than the current stock price, while the lowest is €3.00 (+197.03%) and the highest is €10.00 (+890.10%).
Price Target: €6.50 (+543.56%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for MaaT Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 1 | 2 | 1 |
| Buy | 1 | 1 | 1 | 1 | 0 | 0 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 3 | 3 | 2 |
Financial Forecast
Revenue This Year
9.75M
from 4.52M
Increased by 115.53%
Revenue Next Year
28.88M
from 9.75M
Increased by 196.16%
EPS This Year
-1.91
from -1.95
EPS Next Year
-1.11
from -1.91
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.